-
CM214 - Biomarker Analysis From the Phase 3 CheckMate 214 Trial of Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Advanced Renal Cell Carcinoma (aRCC)
- Description
Description from EGA: "CM214 - Biomarker Analysis From the Phase 3 CheckMate 214 Trial of Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Advanced Renal Cell Carcinoma (aRCC)" Anonymized raw FASTQ files of WES and RNA-seq data from 87 patients who granted informed consent to share such data, are made available at the European Genome-Phenome Archive (EGA)
- Subject
-
Biomarkers, TumorCarcinoma, Renal CellRNA-Seq
- Access Rights
-
Application Required